Chronic airways obstruction in patients with tuberculosis sequelae. A comparison with COPD;Limitación crónica al flujo aéreo en pacientes con secuelas de tuberculosis pulmonar. Caracterización y comparación con EPOC

Revista Chilena de Enfermedades Respiratorias

Volumn 22, Issue 2, 2006, Pages 98-104

  Jiménez P , Patricio ^a,b,c   Torres G , Vivianne ^a   Lehmann F , Paula ^b   Hernández C , Elisa ^b   Alvarez M , Mauricio ^a   Meneses M , Mónica ^a,b   Saldías N , Francisco ^a,b  

^a Hospital Clínico Regional de Valdivia ^*  (Chile)

^b UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^c NONE   (Chile)

Author keywords

6 min walk test; Chronic airway obstruction; COPD; Spirometry; Tuberculosis

Indexed keywords

EID: 33745624287     PISSN: 07175698     EISSN: 07177348     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. DHEDA K, BOOTH H, HUGGETT J H, JOHNSON M A, ZUMLA A, ROOK G A W. Lung Remodeling in Pulmonary Tuberculosis. J Infect Dis 2005; 192: 1201-10.
2. FARGA V. Tuberculosis. Ed. Mediterráneo, Santiago de Chile, 1992, Pág. 35-42.
3. WILLCOX P A, FERGUSON A D. Chronic obstructive airways disease following treated pulmonary tuberculosis. Respir Med 1989; 83: 195-8.
4. HNIZDO E, SINGH T, CHURCHYARD G. Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax 2000; 55: 32-8.
5. AL-HAJJAJ M S. Predictive factors of poor lung function in cured tuberculosis patients. Bahrain Med Bull 2002; 24: 19-22.
6. KRISHNA K, BOND S, ARTVINLI M, et al. Pulmonary function in treated tuberculosis; a long term followup. Am Rev Respir Dis 1977; 115: 402.
7. PAUWELS R A, BUIST A S, CALVERLEY P M, JENKINS C R, HURD S S, the GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-76.
8. http://www.ginasthma.com/GuidelineList.asp Global Strategy for Asthma Management and Prevention. NIH Publication N 02-3659. (Consultada).
9. AMERICAN THORACIC SOCIETY. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-36.
10. STOCKS J, QUANJER P H. Reference values for residual volume, functional residual capacity and total lung capacity. ATS Workshop on lung volume measurements. Official statement of the European Respiratory Society. Eur Respir J 1995; 8: 492-506.
11. ATS Statement: Guidelines for the Six-Minute Walk Test. Am J Respir Crit Care Med 2002; 166: 111-7.
12. PLIT M L, ANDERSON R, VAN RENSBURG C E J, PAGE-SHIPP L, BLOTT J A, FRESEN J L, et al. Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis. Eur Respir J 1998; 12: 351-6.
13. DÍAZ O, VILLAFRANCA C, GHEZZO H, BORZONE G, LEIVA A, MILIC-EMILI J, et al. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J 2000; 16: 269-75.
14. CELLI B R, MACNEE W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of theATS/ERS position paper. Eur Respir J 2004; 23: 932-46.
15. CELLI B R, HALBERT R J, ISONAKA S, SCHAU B. Population impact of different definitions of airway obstruction. Eur Respir J 2003; 22: 268-73.
16. ANCIC P, RIOSECO P, MÉNDEZ E. Hiperreactividad bronquial inespecífica en Tuberculosis Pulmonar inactiva. Rev Méd Chile 1985; 113: 287-90.
17. JONES P W, KAPLAN R M. Methodological issues in evaluating measures of health as outcomes for COPD. Eur Respir J 2003; 21: Suppl 41, 13s-8s.
18. MAHLER D A, HARVER A. A factor analysis of dyspnea ratings, respiratory muscle strength, and lung function in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 145: 467-70.
19. BESTALL J C, PAUL E A, GARROD R, GARNHAM R, JONES P W, WEDZICHA J A. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-6.
20. MARÍN J M, CARRIZO S J, GASCON M, SÁNCHEZ A, GALLEGO B A, CELLI B R. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1395-9.
21. O'DONNELL D E, REVILL S M, WEBB K A. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 770-7.
22. O'DONNELL D E, VODUC N, FITZPATRICK M, WEBB K A. Effect of salmeterol on the ventilatory response to exercise in Chronic Obstructive Pulmonary Disease. Eur Respir J 2004; 24: 86-94.
23. DI MARCO F, MILIC-EMILI J, BOVERI B, CARLUCCI P, SANTUS P, CASANOVA F, et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 2003; 21: 86-94.